Positive news
https://finance.yahoo.com/news/tg-therapeutics-inc-announces-phase-113000232.html
Michael S. Weiss, Executive Chairman and Chief Executive Officer of TG Therapeutics, stated, “Thanks to the hard work of our clinical team, we are excited to open enrollment into our ULTIMATE Phase 3 clinical program. The speed at which our team was able to bring TG-1101 into Phase 3 for Multiple Sclerosis under a Special Protocol Assessment is truly unprecedented and represents an important milestone for us.” Mr. Weiss continued, “We believe B-cell targeted therapy has the potential to become the leading treatment option for MS and that TG-1101 has the potential to differentiate itself amongst the other B-cell targeted therapies by offering a rapid, convenient one hour infusion at an attractive price. We are highly encouraged by the early data seen in our Phase 2 trial and look forward to presenting additional data from that study at the ECTRIMS-ACTRIMS meeting next month.”
Lawrence Steinman, MD, George A. Zimmermann Professor and Professor of Pediatrics, Neurology and Neurological Sciences at Stanford University, and global study chair for both ULTIMATE I and ULTIMATE II trials commented, “The approval of Ocrelizumab as a B-cell targeted therapy for the treatment of Multiple Sclerosis has truly changed the treatment landscape by offering a new method to treat this disease. We are excited to lead this Phase 3 trial and evaluate the unique attributes of ublituximab which may provide a more convenient and possibly less costly treatment option for our patients. At our recently concluded investigator meeting, there was much enthusiasm for this trial and the potential benefits this novel agent may provide our patients.”